Loading ELAN detail
Loading ticker data...
Loading ELAN detail
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals.
It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations.
Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Chart data unavailable
Douglas Lane and Associates LLC cut its stake in Elanco Animal Health Incorporated (NYSE: ELAN) by 11.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,048,092 shares of the company's stock after selling 396,176 shares during the quarter. Douglas Lane
Breaks the flea lifecycle* with Pyriproxyfen, an insect growth regulator, preventing fleas from reinfesting the dog Adjustable collar fits comfortably and securely on a dog of any size Strengthens Elanco's 25-year Advantage brand family Available at pet specialty, dollar, grocery and mass retailers, with a suggested retail price below $25** INDIANAPOLIS, April 9, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the launch of its Advantage™ Collar for Dogs, a new product providing long-lasting protection against two parasites that don't take a season off – fleas and ticks. Designed for dogs and puppies 12 weeks of age and older, this dog collar kills and repels fleas and ticks and repels mosquitoes* for a full four months.
SG Americas Securities LLC trimmed its holdings in Elanco Animal Health Incorporated (NYSE: ELAN) by 25.3% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 95,525 shares of the company's stock after selling 32,403 shares during the period. SG Americas Securities LLC's
Elanco Animal Health Incorporated (NYSE: ELAN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and
Elanco Animal Health (ELAN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Elanco Animal Health Incorporated (ELAN) Presents at 2026 KeyBanc Capital Markets Healthcare Forum Transcript
Elanco Animal Health Incorporated (ELAN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Elanco Animal Health Incorporated (ELAN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Citigroup Inc. reduced its position in Elanco Animal Health Incorporated (NYSE: ELAN) by 75.5% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,058 shares of the company's stock after selling 344,563 shares during the quarter. Citigroup Inc.'s holdings
Elanco Animal Health Incorporated (ELAN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Elanco Animal Health Incorporated (ELAN) Presents at BofA Securities Animal Health Summit Transcript
Elanco Animal Health Incorporated (ELAN) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for Elanco Animal Health (ELAN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.14 per share a year ago.
Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day Outlook Fourth Quarter 2025 Financial Results: Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currency Reported Net Loss of $276 million, Adjusted Net Income of $64 million Adjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7% Reported EPS of $(0.56), Adjusted EPS of $0.13 Full Year 2025 Financial Results: Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025 Revenue of $4,715 million, increased 6% on a reported basis and 7% in organic constant currency Reported Net Loss of $232 million, Adjusted Net Income of $473 million Adjusted EBITDA of $901 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $(0.47), Adjusted EPS of $0.94 Net leverage ratio of 3.6x Adjusted EBITDA Full Year 2026 Guidance: Raising innovation revenue target to $1.15 billion Revenue of $4,950 million to $5,020 million, or 4% to 6% organic constant currency growth Adjusted EBITDA of $955 million to $985 million, an increase of 8% at midpoint Adjusted EPS of $1.00 to $1.06, an increase of 10% at midpoint Year-end net leverage ratio target of 3.1x to 3.3x In line with three-year outlook introduced at December Investor Day, outlining mid-single digit top-line organic constant currency growth, high-single digit Adjusted EBITDA growth, and low double-digit Adjusted EPS growth INDIANAPOLIS, Feb. 24, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2025 and provided initial guidance for both the first quarter and full year 2026. "Elanco delivered significant progress across our strategic priorities of growth, innovation, and cash in 2025," said Jeff Simmons, President and CEO of Elanco.
